Merck Says Bid To Amend Vioxx Investor Suit Is Too Late
Merck & Co. and its former vice president, Edward Scolnick, defendants in litigation alleging the company misrepresented the heart attack risk of its arthritis drug Vioxx, sent letters this week urging...To view the full article, register now.
Already a subscriber? Click here to view full article